173 related articles for article (PubMed ID: 36828547)
1. Antagonism between Prdm16 and Smad4 specifies the trajectory and progression of pancreatic cancer.
Hurwitz E; Parajuli P; Ozkan S; Prunier C; Nguyen TL; Campbell D; Friend C; Bryan AA; Lu TX; Smith SC; Razzaque MS; Xu K; Atfi A
J Cell Biol; 2023 Apr; 222(4):. PubMed ID: 36828547
[TBL] [Abstract][Full Text] [Related]
2. SMAD4 loss triggers the phenotypic changes of pancreatic ductal adenocarcinoma cells.
Chen YW; Hsiao PJ; Weng CC; Kuo KK; Kuo TL; Wu DC; Hung WC; Cheng KH
BMC Cancer; 2014 Mar; 14():181. PubMed ID: 24625091
[TBL] [Abstract][Full Text] [Related]
3. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer.
Bardeesy N; Cheng KH; Berger JH; Chu GC; Pahler J; Olson P; Hezel AF; Horner J; Lauwers GY; Hanahan D; DePinho RA
Genes Dev; 2006 Nov; 20(22):3130-46. PubMed ID: 17114584
[TBL] [Abstract][Full Text] [Related]
4. TGIF1 functions as a tumor suppressor in pancreatic ductal adenocarcinoma.
Parajuli P; Singh P; Wang Z; Li L; Eragamreddi S; Ozkan S; Ferrigno O; Prunier C; Razzaque MS; Xu K; Atfi A
EMBO J; 2019 Jul; 38(13):e101067. PubMed ID: 31268604
[TBL] [Abstract][Full Text] [Related]
5. Integration of Bioinformatics Resources Reveals the Therapeutic Benefits of Gemcitabine and Cell Cycle Intervention in SMAD4-Deleted Pancreatic Ductal Adenocarcinoma.
Hsieh YY; Liu TP; Chou CJ; Chen HY; Lee KH; Yang PM
Genes (Basel); 2019 Sep; 10(10):. PubMed ID: 31569425
[TBL] [Abstract][Full Text] [Related]
6. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer.
Liang C; Shi S; Qin Y; Meng Q; Hua J; Hu Q; Ji S; Zhang B; Xu J; Yu XJ
Gut; 2020 May; 69(5):888-900. PubMed ID: 31611300
[TBL] [Abstract][Full Text] [Related]
7. Tif1γ suppresses murine pancreatic tumoral transformation by a Smad4-independent pathway.
Vincent DF; Gout J; Chuvin N; Arfi V; Pommier RM; Bertolino P; Jonckheere N; Ripoche D; Kaniewski B; Martel S; Langlois JB; Goddard-Léon S; Colombe A; Janier M; Van Seuningen I; Losson R; Valcourt U; Treilleux I; Dubus P; Bardeesy N; Bartholin L
Am J Pathol; 2012 Jun; 180(6):2214-21. PubMed ID: 22469842
[TBL] [Abstract][Full Text] [Related]
8. TET2 Drives 5hmc Marking of GATA6 and Epigenetically Defines Pancreatic Ductal Adenocarcinoma Transcriptional Subtypes.
Eyres M; Lanfredini S; Xu H; Burns A; Blake A; Willenbrock F; Goldin R; Hughes D; Hughes S; Thapa A; Vavoulis D; Hubert A; D'Costa Z; Sabbagh A; Abraham AG; Blancher C; Jones S; Verrill C; Silva M; Soonawalla Z; Maughan T; Schuh A; Mukherjee S; O'Neill E
Gastroenterology; 2021 Aug; 161(2):653-668.e16. PubMed ID: 33915173
[TBL] [Abstract][Full Text] [Related]
9. Down-regulation of microRNA-494 via loss of SMAD4 increases FOXM1 and β-catenin signaling in pancreatic ductal adenocarcinoma cells.
Li L; Li Z; Kong X; Xie D; Jia Z; Jiang W; Cui J; Du Y; Wei D; Huang S; Xie K
Gastroenterology; 2014 Aug; 147(2):485-97.e18. PubMed ID: 24859161
[TBL] [Abstract][Full Text] [Related]
10. Smad4-dependent suppressor pituitary homeobox 2 promotes PPP2R2A-mediated inhibition of Akt pathway in pancreatic cancer.
Wang Q; Li J; Wu W; Shen R; Jiang H; Qian Y; Tang Y; Bai T; Wu S; Wei L; Zang Y; Zhang J; Wang L
Oncotarget; 2016 Mar; 7(10):11208-22. PubMed ID: 26848620
[TBL] [Abstract][Full Text] [Related]
11. Loss of canonical Smad4 signaling promotes KRAS driven malignant transformation of human pancreatic duct epithelial cells and metastasis.
Leung L; Radulovich N; Zhu CQ; Wang D; To C; Ibrahimov E; Tsao MS
PLoS One; 2013; 8(12):e84366. PubMed ID: 24386371
[TBL] [Abstract][Full Text] [Related]
12. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
[TBL] [Abstract][Full Text] [Related]
13. Inactivation of Smad4 accelerates Kras(G12D)-mediated pancreatic neoplasia.
Kojima K; Vickers SM; Adsay NV; Jhala NC; Kim HG; Schoeb TR; Grizzle WE; Klug CA
Cancer Res; 2007 Sep; 67(17):8121-30. PubMed ID: 17804724
[TBL] [Abstract][Full Text] [Related]
14. SMAD4 represses FOSL1 expression and pancreatic cancer metastatic colonization.
Dai C; Rennhack JP; Arnoff TE; Thaker M; Younger ST; Doench JG; Huang AY; Yang A; Aguirre AJ; Wang B; Mun E; O'Connell JT; Huang Y; Labella K; Talamas JA; Li J; Ilic N; Hwang J; Hong AL; Giacomelli AO; Gjoerup O; Root DE; Hahn WC
Cell Rep; 2021 Jul; 36(4):109443. PubMed ID: 34320363
[TBL] [Abstract][Full Text] [Related]
15. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status.
Liang C; Xu J; Meng Q; Zhang B; Liu J; Hua J; Zhang Y; Shi S; Yu X
Autophagy; 2020 Mar; 16(3):486-500. PubMed ID: 31177911
[TBL] [Abstract][Full Text] [Related]
16. AGR2 is a SMAD4-suppressible gene that modulates MUC1 levels and promotes the initiation and progression of pancreatic intraepithelial neoplasia.
Norris AM; Gore A; Balboni A; Young A; Longnecker DS; Korc M
Oncogene; 2013 Aug; 32(33):3867-76. PubMed ID: 22945649
[TBL] [Abstract][Full Text] [Related]
17. SMAD4 endows TGF-β1-induced highly invasive tumor cells with ferroptosis vulnerability in pancreatic cancer.
Chen HD; Ye Z; Hu HF; Fan GX; Hu YH; Li Z; Li BR; Ji SR; Zhou CJ; Xu XW; Yu XJ; Qin Y
Acta Pharmacol Sin; 2024 Apr; 45(4):844-856. PubMed ID: 38057506
[TBL] [Abstract][Full Text] [Related]
18. The role of chromosome 18 abnormalities in the progression of pancreatic adenocarcinoma.
Sunamura M; Lefter LP; Duda DG; Morita R; Inoue H; Yokoyama T; Yatsuoka T; Abe T; Egawa S; Furukawa T; Fukushige S; Oshimura M; Horii A; Matsuno S
Pancreas; 2004 Apr; 28(3):311-6. PubMed ID: 15084978
[TBL] [Abstract][Full Text] [Related]
19. SMAD4 Y353C promotes the progression of PDAC.
Wang Z; Li Y; Zhan S; Zhang L; Zhang S; Tang Q; Li M; Tan Z; Liu S; Xing X
BMC Cancer; 2019 Nov; 19(1):1037. PubMed ID: 31684910
[TBL] [Abstract][Full Text] [Related]
20. Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1.
Radke DI; Ungefroren H; Helm O; Voigt S; Alp G; Braun H; Hübner S; Dilchert J; Sebens S; Adam D; Kalthoff H; Trauzold A
Cell Signal; 2016 Nov; 28(11):1652-62. PubMed ID: 27492861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]